Skip to main content

Brazilian Outlook

Galderma Slumps After FDA Turns Down Botox Rival Relfydess




Galderma’s shares slumped the most in more than a year after US regulators turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *